Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBISU Study: Symptom and quality-of-life changes with BGF pMDI in COPD
jRCT1031210548Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Breztri Aerosphere in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Primary endpoint: Mean change from baseline in CAT total score over 12 weeks. Started Jan 2022; status: completed.
02
Drugs
Breztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT1031210548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210548.